| __timestamp | ADMA Biologics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 3243000 |
| Thursday, January 1, 2015 | 4311461 | 2472000 |
| Friday, January 1, 2016 | 6360761 | 2548000 |
| Sunday, January 1, 2017 | 29164321 | 19623000 |
| Monday, January 1, 2018 | 42194635 | 30421000 |
| Tuesday, January 1, 2019 | 39504238 | 32793999 |
| Wednesday, January 1, 2020 | 61291426 | 28304000 |
| Friday, January 1, 2021 | 79769341 | 620000 |
| Saturday, January 1, 2022 | 118814535 | 755000 |
| Sunday, January 1, 2023 | 169273000 | 1322000 |
Unleashing the power of data
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for ADMA Biologics, Inc. and Viridian Therapeutics, Inc. from 2014 to 2023. Over this period, ADMA Biologics has shown a significant increase in its cost of revenue, rising by approximately 4,400% from 2014 to 2023. In contrast, Viridian Therapeutics experienced a more modest increase of around 40% during the same timeframe.
The data reveals a stark contrast in financial strategies, with ADMA's costs peaking in 2023, while Viridian's costs remained relatively stable, even decreasing in some years. This divergence highlights the different operational approaches and market strategies employed by these companies. Understanding these trends provides valuable insights into the financial health and strategic priorities of these biotech firms.
Cost of Revenue: Key Insights for GSK plc and Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Walgreens Boots Alliance, Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Pharming Group N.V. vs ADMA Biologics, Inc.
Analyzing Cost of Revenue: Cytokinetics, Incorporated and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Viridian Therapeutics, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Geron Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Iovance Biotherapeutics, Inc. vs Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Viridian Therapeutics, Inc.